PRESS RELEASE

PRESS RELEASE

View printer-friendly version << Back

Novavax to Present at Two Upcoming Investor Conferences

GAITHERSBURG, Md., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (NASDAQ: NVAX) today announced that it will present at the Ladenburg Thalmann 2018 Healthcare Conference and the Cantor Global Healthcare Conference 2018, both in the first week of October.

Conference details are as follows:

Ladenburg Thalmann 2018 Healthcare Conference

Date and Time:
Location:
Live webcast:
  Tuesday, October 2, 12:00 p.m. – 12:25 p.m.
Track 5, Montmartre, Sofitel New York
www.novavax.com, “Investors”/“Events”
     

Cantor Global Healthcare Conference 2018

Date and Time:
Location:
Live webcast:
  Wednesday, October 3, 10:55 a.m. – 11:25 p.m.
Track 2, Empire Ballroom 1, InterContinental New York Barclay Hotel
www.novavax.com, “Investors”/“Events”
     

A replay of the presentations will also be accessible under the “Investors/Events” section www.novavax.com.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that drives improved health globally through the discovery and development of innovative vaccines to prevent serious respiratory diseases. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is poised to help prevent the second leading cause of death in children under one year of age worldwide. Novavax is also advancing NanoFlu™, its quadrivalent influenza nanoparticle vaccine, to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Contact:

Investors
Novavax, Inc.
Erika Trahan
Senior Manager, Investor & Public Relations
ir@novavax.com
240-268-2000

Westwicke Partners
John Woolford
john.woolford@westwicke.com
443-213-0506

Media
Sam Brown
Mike Beyer
mikebeyer@sambrown.com
312-961-2502

Novavax logo

Source: Novavax, Inc.